Emerald Mutual Fund Advisers Trust Purchases Shares of 17,850 Twist Bioscience Corporation $TWST

Emerald Mutual Fund Advisers Trust purchased a new stake in Twist Bioscience Corporation (NASDAQ:TWST) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 17,850 shares of the company’s stock, valued at approximately $848,000.

A number of other institutional investors have also made changes to their positions in the business. Stifel Financial Corp lifted its position in shares of Twist Bioscience by 3.6% during the 4th quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock worth $246,000 after purchasing an additional 271 shares during the last quarter. D.A. Davidson & CO. grew its holdings in Twist Bioscience by 1.2% in the 4th quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock valued at $801,000 after buying an additional 305 shares during the last quarter. CWM LLC increased its position in Twist Bioscience by 9.4% in the 4th quarter. CWM LLC now owns 4,738 shares of the company’s stock worth $150,000 after buying an additional 407 shares during the period. California State Teachers Retirement System increased its position in Twist Bioscience by 0.8% in the 2nd quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after buying an additional 442 shares during the period. Finally, SBI Securities Co. Ltd. lifted its holdings in shares of Twist Bioscience by 68.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after buying an additional 571 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TWST shares. Piper Sandler started coverage on Twist Bioscience in a research report on Thursday, June 11th. They issued an “overweight” rating and a $85.00 price objective for the company. Canaccord Genuity Group boosted their target price on shares of Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a research report on Tuesday. Robert W. Baird upped their target price on shares of Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a report on Wednesday, June 24th. Finally, UBS Group set a $89.00 price target on shares of Twist Bioscience in a research report on Monday, June 15th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.30.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 18,880 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $95.00, for a total value of $1,793,600.00. Following the sale, the chief executive officer owned 824,039 shares of the company’s stock, valued at $78,283,705. The trade was a 2.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa A. Starovasnik sold 500 shares of the stock in a transaction on Monday, April 27th. The shares were sold at an average price of $61.83, for a total transaction of $30,915.00. Following the completion of the transaction, the director owned 25,222 shares of the company’s stock, valued at approximately $1,559,476.26. This represents a 1.94% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 64,382 shares of company stock valued at $5,101,215 over the last 90 days. Corporate insiders own 3.08% of the company’s stock.

Twist Bioscience Trading Up 2.4%

Twist Bioscience stock opened at $92.53 on Wednesday. The business has a 50 day moving average price of $75.69 and a two-hundred day moving average price of $56.93. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $105.47. The stock has a market cap of $5.76 billion, a price-to-earnings ratio of -69.57 and a beta of 2.11.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The firm had revenue of $110.72 million for the quarter, compared to analyst estimates of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.Twist Bioscience’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.66) EPS. As a group, equities analysts forecast that Twist Bioscience Corporation will post -2.02 EPS for the current year.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.